Loading...

Inogen

Nasdaq:INGN
Snowflake Description

Flawless balance sheet with solid track record.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
INGN
Nasdaq
$2B
Market Cap
  1. Home
  2. US
  3. Healthcare
Company description

Inogen, Inc., a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. The last earnings update was 22 days ago. More info.


Add to Portfolio Compare Print
  • Inogen has significant price volatility in the past 3 months.
INGN Share Price and Events
7 Day Returns
-1.4%
NasdaqGS:INGN
1.1%
US Medical Equipment
1.6%
US Market
1 Year Returns
-23.4%
NasdaqGS:INGN
20.3%
US Medical Equipment
3.2%
US Market
INGN Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Inogen (INGN) -1.4% -32.3% -16.8% -23.4% 134% 474.1%
US Medical Equipment 1.1% 2.6% 13.6% 20.3% 70.3% 98.3%
US Market 1.6% 2.1% 12.8% 3.2% 38.6% 43.6%
1 Year Return vs Industry and Market
  • INGN underperformed the Medical Equipment industry which returned 20.3% over the past year.
  • INGN underperformed the Market in United States of America which returned 3.2% over the past year.
Price Volatility
INGN
Industry
5yr Volatility vs Market

Value

 Is Inogen undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Inogen to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data    Our intrinsic value calculation method has changed recently, learn more here.

Below are the data sources, inputs and calculation used to determine the intrinsic value for Inogen.

NasdaqGS:INGN Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 7 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8.4%
Perpetual Growth Rate 10-Year US Government Bond Rate 2.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for NasdaqGS:INGN
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 2.7%
Equity Risk Premium S&P Global 6%
Medical Equipment Unlevered Beta Simply Wall St/ S&P Global 0.93
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.931 (1 + (1- 21%) (0%))
0.954
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.95
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (0.954 * 5.96%)
8.41%

Discounted Cash Flow Calculation for NasdaqGS:INGN using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Inogen is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

NasdaqGS:INGN DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 8.41%)
2019 64.00 Analyst x1 59.03
2020 89.00 Analyst x1 75.72
2021 102.90 Est @ 15.62% 80.75
2022 114.99 Est @ 11.75% 83.24
2023 125.40 Est @ 9.05% 83.73
2024 134.36 Est @ 7.15% 82.75
2025 142.19 Est @ 5.82% 80.77
2026 149.15 Est @ 4.9% 78.15
2027 155.48 Est @ 4.25% 75.15
2028 161.38 Est @ 3.79% 71.94
Present value of next 10 years cash flows $771.25
NasdaqGS:INGN DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $161.38 × (1 + 2.73%) ÷ (8.41% – 2.73%)
$2,916.79
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $2,916.79 ÷ (1 + 8.41%)10
$1,300.35
NasdaqGS:INGN Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $771.25 + $1,300.35
$2,071.59
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $2,071.59 / 21.81
$94.96
NasdaqGS:INGN Discount to Share Price
Calculation Result
Value per share (USD) From above. $94.96
Current discount Discount to share price of $96.11
= -1 x ($96.11 - $94.96) / $94.96
-1.2%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Inogen is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Inogen's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Inogen's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGS:INGN PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $2.44
NasdaqGS:INGN Share Price ** NasdaqGS (2019-03-19) in USD $96.11
United States of America Medical Equipment Industry PE Ratio Median Figure of 63 Publicly-Listed Medical Equipment Companies 39.26x
United States of America Market PE Ratio Median Figure of 3,056 Publicly-Listed Companies 17.77x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Inogen.

NasdaqGS:INGN PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:INGN Share Price ÷ EPS (both in USD)

= 96.11 ÷ 2.44

39.42x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Inogen is overvalued based on earnings compared to the US Medical Equipment industry average.
  • Inogen is overvalued based on earnings compared to the United States of America market.
Price based on expected Growth
Does Inogen's expected growth come at a high price?
Raw Data
NasdaqGS:INGN PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 39.42x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 7 Analysts
11.2%per year
United States of America Medical Equipment Industry PEG Ratio Median Figure of 53 Publicly-Listed Medical Equipment Companies 2.59x
United States of America Market PEG Ratio Median Figure of 2,107 Publicly-Listed Companies 1.49x

*Line of best fit is calculated by linear regression .

NasdaqGS:INGN PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 39.42x ÷ 11.2%

3.52x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Inogen is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on Inogen's assets?
Raw Data
NasdaqGS:INGN PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $14.25
NasdaqGS:INGN Share Price * NasdaqGS (2019-03-19) in USD $96.11
United States of America Medical Equipment Industry PB Ratio Median Figure of 187 Publicly-Listed Medical Equipment Companies 4.44x
United States of America Market PB Ratio Median Figure of 5,154 Publicly-Listed Companies 1.89x
NasdaqGS:INGN PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:INGN Share Price ÷ Book Value per Share (both in USD)

= 96.11 ÷ 14.25

6.74x

* Primary Listing of Inogen.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Inogen is overvalued based on assets compared to the US Medical Equipment industry average.
X
Value checks
We assess Inogen's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
  5. Inogen has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Inogen expected to perform in the next 1 to 3 years based on estimates from 7 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
11.2%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Inogen expected to grow at an attractive rate?
  • Inogen's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
  • Inogen's earnings growth is positive but not above the United States of America market average.
  • Inogen's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGS:INGN Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGS:INGN Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 7 Analysts 11.2%
NasdaqGS:INGN Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 7 Analysts 14.6%
United States of America Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 20.5%
United States of America Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 7.3%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 14.3%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.1%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGS:INGN Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGS:INGN Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 787 91 1
2022-12-31 680 76 2
2021-12-31 591 69 3
2020-12-31 517 97 56 7
2019-12-31 435 74 44 7
NasdaqGS:INGN Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 358 60 52
2018-09-30 335 61 41
2018-06-30 309 64 32
2018-03-31 276 60 26
2017-12-31 249 60 21
2017-09-30 237 53 27
2017-06-30 222 44 25
2017-03-31 212 39 24
2016-12-31 203 31 21
2016-09-30 192 38 19
2016-06-30 179 41 17
2016-03-31 168 37 13

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Inogen's earnings are expected to grow by 11.2% yearly, however this is not considered high growth (20% yearly).
  • Inogen's revenue is expected to grow by 14.6% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGS:INGN Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below

All data from Inogen Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:INGN Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 3.94 3.94 3.94 1.00
2022-12-31 3.26 3.26 3.26 1.00
2021-12-31 2.90 3.17 2.71 3.00
2020-12-31 2.39 2.59 2.16 5.00
2019-12-31 1.93 2.16 1.84 5.00
NasdaqGS:INGN Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 2.44
2018-09-30 1.95
2018-06-30 1.53
2018-03-31 1.24
2017-12-31 1.02
2017-09-30 1.31
2017-06-30 1.21
2017-03-31 1.18
2016-12-31 1.02
2016-09-30 0.96
2016-06-30 0.84
2016-03-31 0.64

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Inogen is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess Inogen's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Inogen has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Inogen performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Inogen's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Inogen has delivered over 20% year on year earnings growth in the past 5 years.
  • Inogen's 1-year earnings growth exceeds its 5-year average (146.9% vs 46.8%)
  • Inogen's earnings growth has exceeded the US Medical Equipment industry average in the past year (146.9% vs 31.2%).
Earnings and Revenue History
Inogen's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Inogen Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:INGN Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 358.11 51.85 133.66 7.03
2018-09-30 335.37 41.19 119.73 6.66
2018-06-30 309.11 32.10 106.88 5.94
2018-03-31 275.99 25.83 96.01 5.42
2017-12-31 249.44 21.00 87.26 5.31
2017-09-30 236.50 26.87 81.44 5.16
2017-06-30 221.89 24.78 76.36 5.14
2017-03-31 212.34 23.93 72.36 5.25
2016-12-31 202.83 20.52 69.33 5.11
2016-09-30 192.42 19.12 67.37 5.12
2016-06-30 178.78 16.57 63.53 4.89
2016-03-31 168.24 12.53 60.22 4.49
2015-12-31 159.01 11.59 57.03 4.18
2015-09-30 147.68 9.24 53.41 3.62
2015-06-30 136.29 8.55 49.15 3.30
2015-03-31 122.66 6.94 44.92 3.21
2014-12-31 112.54 5.27 42.03 2.98
2014-09-30 103.18 5.86 39.35 2.89
2014-06-30 93.57 2.78 37.15 2.77
2014-03-31 83.33 1.11 34.90 2.53
2013-12-31 75.44 0.21 32.13 2.40
2013-09-30 69.52 -3.45 29.39 2.35
2013-06-30 62.90 -3.75 26.84 2.23
2013-03-31 53.53 -5.07 23.33 2.18
2012-12-31 48.58 -5.22 20.86 2.26

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Inogen has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Inogen used its assets more efficiently than the US Medical Equipment industry average last year based on Return on Assets.
  • Inogen has improved its use of capital last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Inogen's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Inogen has a total score of 5/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Inogen's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Inogen's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Inogen is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Inogen's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Inogen's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Inogen has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Inogen Company Filings, last reported 2 months ago.

NasdaqGS:INGN Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 310.42 0.00 240.35
2018-09-30 291.26 0.00 223.86
2018-06-30 266.91 0.00 208.41
2018-03-31 246.34 0.00 188.30
2017-12-31 227.04 0.00 173.94
2017-09-30 221.29 0.00 163.09
2017-06-30 207.78 0.00 144.21
2017-03-31 192.78 0.00 128.24
2016-12-31 182.09 0.00 113.88
2016-09-30 156.08 0.08 108.34
2016-06-30 147.50 0.16 98.12
2016-03-31 138.19 0.24 86.09
2015-12-31 134.02 0.32 82.90
2015-09-30 129.92 0.39 74.12
2015-06-30 127.92 0.47 66.06
2015-03-31 122.57 0.54 61.10
2014-12-31 118.15 0.61 56.84
2014-09-30 113.91 0.66 56.16
2014-06-30 110.81 13.41 69.05
2014-03-31 107.90 9.19 59.55
2013-12-31 56.56 10.65 13.52
2013-09-30 34.40 12.03 17.06
2013-06-30 32.95 9.00 14.17
2013-03-31 28.74 8.94 15.11
2012-12-31 28.74 8.94 15.11
  • Inogen has no debt.
  • Inogen has no debt compared to 5 years ago when it was 18.6%.
  • Inogen has no debt, it does not need to be covered by operating cash flow.
  • Inogen has no debt, therefore coverage of interest payments is not a concern.
X
Financial health checks
We assess Inogen's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Inogen has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Inogen's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Inogen dividends.
If you bought $2,000 of Inogen shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Inogen's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Inogen's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGS:INGN Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below
United States of America Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 24 Stocks 1.3%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2004 Stocks 2.5%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGS:INGN Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Inogen has not reported any payouts.
  • Unable to verify if Inogen's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Inogen's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Inogen has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Inogen's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Inogen afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Inogen has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Inogen's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Scott Wilkinson
COMPENSATION $2,848,366
AGE 53
TENURE AS CEO 2 years
CEO Bio

Mr. Scott Wilkinson has been the Chief Executive Officer of Inogen, Inc. since March 1, 2017 and as its President since January 1, 2016. Mr. Wilkinson served as the Chief Operating Officer of Inogen, Inc. from January 1, 2016 to March 1, 2017. Mr. Wilkinson served as an Executive Vice President of Sales & Marketing at Inogen, Inc. since 2008 until December 31, 2015. Mr. Wilkinson served as Senior Vice President of Product Management at Inogen, Inc. Mr. Wilkinson has 20 years experience and a diverse background in Product Management, Operations and Research & Development. Mr. Wilkinson served as Group Product Manager for Oxygen Therapy at Invacare Corporation where he led the introduction of the HomeFill II Oxygen System. He has additional medical device management experience as a Product Line Director of Johnson & Johnson and a Product Manager of Kimberly-Clark Corporation in the Professional Health Care Sector. He has been Director of Inogen, Inc. since January 1, 2017. Mr. Wilkinson received a Bachelor’s degree in Chemical Engineering from the University of Akron and an MBA from University of Wisconsin, Oshkosh.

CEO Compensation
  • Scott's compensation has increased by more than 20% in the past year.
  • Scott's remuneration is about average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Inogen management team in years:

2.2
Average Tenure
39
Average Age
  • The tenure for the Inogen management team is about average.
Management Team

Scott Wilkinson

TITLE
CEO, President & Director
COMPENSATION
$3M
AGE
53
TENURE
2 yrs

Brenton Taylor

TITLE
Executive Vice President of Engineering
COMPENSATION
$793K
AGE
37
TENURE
18.2 yrs

Ali Bauerlein

TITLE
Executive VP of Finance
COMPENSATION
$1M
AGE
37
TENURE
18.2 yrs

Byron Myers

TITLE
Executive Vice President of Sales & Marketing
COMPENSATION
$919K
AGE
39
TENURE
2.2 yrs

Bart Sanford

TITLE
Executive Vice President of Operations
AGE
52
TENURE
0.5 yrs

Matt Bacso

TITLE
Investor Relations & Corporate Development Manager
Board of Directors Tenure

Average tenure and age of the Inogen board of directors in years:

4.6
Average Tenure
58
Average Age
  • The tenure for the Inogen board of directors is about average.
Board of Directors

Heath Lukatch

TITLE
Chairman of the Board
COMPENSATION
$436K
AGE
51
TENURE
11.2 yrs

Scott Wilkinson

TITLE
CEO, President & Director
COMPENSATION
$3M
AGE
53
TENURE
2.2 yrs

R. Greer

TITLE
Independent Director
COMPENSATION
$329K
AGE
60
TENURE
3.6 yrs

Loren McFarland

TITLE
Independent Director
COMPENSATION
$388K
AGE
59
TENURE
6.2 yrs

Heather Rider

TITLE
Independent Director
COMPENSATION
$327K
AGE
58
TENURE
4.6 yrs

Richard Casaburi

TITLE
Member of Advisory Board

Jeffrey Kupperman

TITLE
Member of Advisory Board

Paul Selecky

TITLE
Member of Advisory Board

Neil MacIntyre

TITLE
Member of Advisory Board

Robert Chatburn

TITLE
Member of Advisory Board
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
X
Management checks
We assess Inogen's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Inogen has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Introducing Inogen (NASDAQ:INGN), The Stock That Soared 460% In The Last Five Years

(NASDAQ:INGN) shareholders have seen the share price descend 29% over the month. … The most important thing for savvy investors to consider is whether the underlying business can justify the share price gain. … One way to examine how market sentiment has changed over time is to look at the interaction between a company's share price and its earnings per share (EPS).

Simply Wall St -

What Should You Know About Inogen, Inc.'s (NASDAQ:INGN) Growth?

Inogen, Inc.'s (NASDAQ:INGN) released its most recent earnings update in December 2018, whicha … signalled

Simply Wall St -

Here's What Inogen, Inc.'s (NASDAQ:INGN) P/E Is Telling Us

This article is for investors who would like to improve their understanding of price to earnings ratios (P/E ratios). … Inogen has a price to earnings ratio of 71.19, based on the last twelve months. … How Do I Calculate A Price To Earnings Ratio

Simply Wall St -

A Closer Look At Inogen, Inc.'s (NASDAQ:INGN) Impressive ROE

With that in mind, this article will work through how we can use Return On Equity (ROE) to better understand a business. … Another way to think of that is that for every $1 worth of equity in the company, it was able to earn $0.14. … Return on Equity = Net Profit ÷ Shareholders' Equity

Simply Wall St -

Inogen, Inc. (NASDAQ:INGN): Can Growth Justify Its January Share Price?

Let’s take a look at some key metrics to determine whether there's any value here for current and potential future investors. … Want to help shape the future of investing tools. … Investors in Inogen have been patiently waiting for the uptick in earnings.

Simply Wall St -

Has Inogen, Inc. (NASDAQ:INGN) Got Enough Cash?

Today we will look at INGN’s financial liquidity and debt levels, which are strong indicators for whether the company can weather economic downturns or fund strategic acquisitions for future growth. … Remember this is a very top-level look that focuses exclusively on financial health, so I recommend a deeper analysis. … Want to help shape the future of investing tools and platforms

Simply Wall St -

What Are Analysts Saying About Inogen, Inc.'s (NASDAQ:INGN) Growth?

(NASDAQ:INGN) released its earnings update. … with earnings expected to grow by 19% in the upcoming year … the higher past 5-year average growth rate of 48%

Simply Wall St -

An Examination Of Inogen, Inc. (NASDAQ:INGN)

(NASDAQ:INGN) is a company with exceptional fundamental characteristics. … Upon building up an investment case for a stock, we should look at various aspects. … is a company with great financial health as well as a.

Simply Wall St -

Why You Should Buy Inogen Inc (NASDAQ:INGN) In This Bear Market

High quality stocks such as Inogen Inc has fared well over time in a fickle stock market, which is why I want to bring it into light amongst all the chaos. … Below I take a look at three key features of what makes a robust defensive stock investment: its size, financial health and track record. … Inogen, Inc., a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally

Simply Wall St -

What Does Inogen Inc's (NASDAQ:INGN) P/E Ratio Tell You?

This article is written for those who want to get better at using price to earnings ratios (P/E ratios). … We'll look at Inogen Inc's (NASDAQ:INGN) P/E ratio and reflect on what it tells us about the company's share price. … Price to Earnings Ratio = Share Price ÷ Earnings per Share (EPS)

Simply Wall St -

Company Info

Description

Inogen, Inc., a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company offers Inogen One, a portable device that concentrate the air around the patient to provide a single source of supplemental oxygen; and Inogen At Home stationary oxygen concentrators, as well as related accessories. The company also rents its products directly to patients. Inogen, Inc. was founded in 2001 and is headquartered in Goleta, California.

Details
Name: Inogen, Inc.
INGN
Exchange: NasdaqGS
Founded: 2001
$2,096,629,558
21,814,895
Website: http://www.inogen.com
Address: Inogen, Inc.
326 Bollay Drive,
Goleta,
California, 93117,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS INGN Common Stock Nasdaq Global Select US USD 14. Feb 2014
DB 6IO Common Stock Deutsche Boerse AG DE EUR 14. Feb 2014
Number of employees
Current staff
Staff numbers
1,099
Inogen employees.
Industry
Health Care Equipment
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/03/20 00:33
End of day share price update: 2019/03/19 00:00
Last estimates confirmation: 2019/02/27
Last earnings filing: 2019/02/26
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.